<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00717210</url>
  </required_header>
  <id_info>
    <org_study_id>NOA-04</org_study_id>
    <nct_id>NCT00717210</nct_id>
  </id_info>
  <brief_title>Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide</brief_title>
  <acronym>NOA-04</acronym>
  <official_title>NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuro-Oncology Working Group of the German Cancer Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neuro-Oncology Working Group of the German Cancer Society</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: The optimal treatment of anaplastic gliomas is controversial. Standard of care in
      most centers is still radiotherapy. This phase III study compared the efficacy and safety of
      radiotherapy vs chemotherapy in patients (pts) with newly-diagnosed, supratentorial gliomas
      of WHO grade III.

      Methods: Pts were randomized 2:1:1 between June 1999 and February 2005 in 34 German centers
      to receive (i) a 6-week course of radiotherapy (1,8-2 Gy fractions, total dose 54-60 Gy) or
      (ii) four 6-week cycles of CCNU at 110 mg mg/m2 on day 1, vincristine at 2 mg on days 8 and
      29 and procarbazine at 60 mg/m2 on days 8-21 or eight 4-week cycles of 200 mg/m2 temozolomide
      on days 1-5. Treatment was stopped prematurely at disease progression or occurrence of
      unacceptable toxicity. At this time or at disease progression, treatment in the radiotherapy
      group was continued with one of the chemotherapies (1:1 randomization) and with radiotherapy
      in both chemotherapy groups. The primary endpoint was time-to-treatment-failure (TTF) defined
      as progression after radiotherapy and one chemotherapy in either sequence, or any time before
      if further therapy could not be employed. Assuming a 50% improvement in TTF of starting with
      chemotherapy, 318 pts were to be enrolled to provide 80% power to achieve statistical
      significance at a one-sided level of 0.05.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 1999</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-to-treatment-failure defined as progression after radiotherapy and one chemotherapy in either sequence</measure>
    <time_frame>1999-2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival Overall Survival Toxicity Response rates</measure>
    <time_frame>1999-2012</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">318</enrollment>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Oligodendroglioma</condition>
  <condition>Oligoastrocytoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional Radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1/2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1:1 randomization between temozolomide and procarbazine/lomustine/vincristine (PCV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>200 mg/m2 body surface on days 1-5 every 28 days for 8 cycles; and again for another 4 cycles at primary progression</description>
    <arm_group_label>B1/2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Focal radiotherapy</intervention_name>
    <description>54-60 Gy in 28-30 fractions over 6-7 weeks</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent

          -  centrally confirmed anaplastic glioma according to the WHO-classification 1998/2000

          -  age ≥ 18 years

          -  Karnofsky performance status (KPS) of 70 or higher

          -  no prior systemic chemotherapy or radiation therapy of the brain

          -  no HIV infection

          -  adequate bone marrow reserve, liver function, and renal function

          -  Patients on corticosteroids had to be on a stable or decreasing dosage within the 14
             days prior to randomization

        Exclusion Criteria:

          -  Glioblastoma

          -  infratentorial localization of the tumor

          -  pregnancy or lactation period

          -  serious medical or neurological comorbidity

          -  additional malignancy requiring radio- or chemotherapy

          -  known hypersensitivity against study drugs

          -  inability to swallow

          -  frequent emesis

          -  psychological. familial, sociological or geographical situations impairing compliance
             with F/U examinations

          -  parallel participation in other studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Weller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, University of Zurich, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Wick, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Neurooncology, University of Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology and Radiotherapy</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nervenklinik</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurosurgery</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiotherapy</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurosurgery</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurosurgery</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurosurgery</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County District Hospital</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.neuroonkologie.de</url>
    <description>Homepage of the NOA</description>
  </link>
  <results_reference>
    <citation>Wick W, Weller M for the Neurooncology Working Group (NOA) of the German Cancer Society Randomized phase -III study of sequential radiochemotherapy of oligoastrocytic tumors of WHO-grade III with PCV or temozolomide: NOA-04. J Clin Oncol 2008;26(15S):2007.</citation>
  </results_reference>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2008</study_first_submitted>
  <study_first_submitted_qc>July 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2008</study_first_posted>
  <last_update_submitted>July 16, 2008</last_update_submitted>
  <last_update_submitted_qc>July 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Michael Weller</name_title>
    <organization>NOA</organization>
  </responsible_party>
  <keyword>1p/19q loss</keyword>
  <keyword>MGMT</keyword>
  <keyword>prognostic factors</keyword>
  <keyword>PCV</keyword>
  <keyword>temozolomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

